Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AB-3028 |
| Trade Name | |
| Synonyms | AB3028|AB 3028 |
| Drug Descriptions |
AB-3028 comprises autologous T-lymphocytes engineered to express a logic-gated chimeric antigen receptor (CAR) targeting tumor antigens and shRNA-miR modules targeting FAS and TGFBR2, which potentially inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 256). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AB-3028 | AB-3028 | 0 | 1 |